Bio-Rad Laboratories Inc (BIO)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 53.77% | 54.41% | 54.00% | 53.37% | 53.40% | 53.58% | 54.02% | 55.03% | 56.04% | 56.13% | 57.05% | 56.76% | 56.14% | 57.05% | 56.59% | 56.32% | 56.48% | 54.96% | 54.40% | 54.20% |
| Operating profit margin | 10.72% | 12.19% | 13.31% | 12.68% | 14.63% | 15.13% | 14.93% | 15.98% | 16.95% | 16.52% | 18.37% | 18.37% | 16.75% | 18.72% | 17.73% | 16.20% | 16.14% | 12.39% | 10.59% | 10.62% |
| Pretax margin | -91.27% | -38.96% | -67.50% | -17.04% | -31.82% | -6.88% | -19.27% | -9.21% | -168.14% | -279.57% | -90.90% | -7.94% | 186.08% | 287.11% | 181.16% | 196.47% | 192.79% | 190.26% | 109.39% | 87.26% |
| Net profit margin | -71.86% | -30.18% | -51.73% | -12.37% | -23.86% | -5.64% | -15.31% | -6.80% | -129.45% | -215.16% | -67.66% | -3.49% | 145.28% | 223.47% | 140.48% | 151.73% | 149.52% | 147.91% | 84.89% | 67.80% |
Bio-Rad Laboratories Inc's profitability ratios show fluctuating trends over the analyzed periods. The company's Gross Profit Margin improved from 54.20% in March 2020 to a peak of 57.05% in September 2021, but declined to 53.77% by December 2024.
In terms of Operating Profit Margin, there was a notable increase from 10.62% in March 2020 to a peak of 18.72% in September 2021. However, the margin gradually decreased to 10.72% by December 2024.
The Pretax Margin exhibited significant fluctuations, ranging from a high of 287.11% in September 2021 to a low of -279.57% in September 2022. This indicates significant variability in the company's ability to generate profits before considering taxes.
The Net Profit Margin also showed inconsistency, with a peak of 223.47% in September 2021 and a low of -215.16% in September 2022. The margins were negative in the latter part of the analyzed period, reflecting the company's challenges in generating profits after accounting for all expenses.
Overall, Bio-Rad Laboratories Inc's profitability ratios demonstrate a mix of improvements and declines, indicating fluctuations in the company's ability to generate profits over the analyzed periods. It is essential for stakeholders to closely monitor these ratios to assess the company's financial health and performance accurately.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 2.94% | 2.97% | 3.52% | 2.62% | 3.18% | 3.46% | 3.45% | 3.25% | 3.52% | 3.84% | 4.16% | 3.70% | 2.75% | 2.79% | 3.38% | 3.14% | 3.17% | 2.45% | 2.40% | 2.85% |
| Return on assets (ROA) | -19.69% | -7.34% | -13.68% | -2.56% | -5.18% | -1.29% | -3.54% | -1.38% | -26.87% | -50.05% | -15.32% | -0.70% | 23.89% | 33.37% | 26.76% | 29.41% | 29.34% | 29.29% | 19.28% | 18.19% |
| Return on total capital | -34.91% | -12.77% | -25.51% | 12.71% | 8.69% | 5.20% | 5.09% | 4.55% | 4.94% | 5.60% | 6.02% | 5.32% | 3.78% | 3.77% | 4.59% | 4.49% | 4.41% | 3.58% | 3.63% | 4.10% |
| Return on equity (ROE) | -28.07% | -10.40% | -19.56% | -3.56% | -7.29% | -1.82% | -5.02% | -1.94% | -37.73% | -71.39% | -21.77% | -0.99% | 31.07% | 43.43% | 34.89% | 38.63% | 38.53% | 39.89% | 26.48% | 25.10% |
Bio-Rad Laboratories Inc has shown fluctuations in its profitability ratios over the past few years. The Operating Return on Assets (Operating ROA) has ranged from 2.40% to 4.16%, with a general increasing trend since March 2020. This indicates that the company has been able to generate more operating income relative to its total assets.
The Return on Assets (ROA) has been volatile, ranging from -50.05% to 33.37%. However, it has generally been negative since March 2022, suggesting that the company's net income has been insufficient to cover its total assets.
The Return on Total Capital has varied between -34.91% and 12.71%, with significant negative values in the last few quarters. This indicates that the company has not been efficiently generating returns for both equity and debt providers.
Lastly, the Return on Equity (ROE) has fluctuated widely, from -71.39% to 43.43%, with negative values dominating since March 2022. This implies that the company has struggled to provide returns to its shareholders.
Overall, Bio-Rad Laboratories Inc has experienced challenges in profitability, with inconsistent performance across different profitability ratios in recent quarters.